pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,204 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1171Endpoints885BioPharma Dive340BioSpace304Fierce Biotech285onclive165raps104globenewswire health73
therapy area
allOncology7505Rare Disease1856Cardiology1708Immunology1472Hematology1313Vaccines1192Pulmonology
  • Weight-loss doctor warns against unproven GLP-1 microdosing for cosmetic use
    Dr. Jody Dushay, a Harvard‑affiliated weight‑loss specialist, says patients are asking about tiny doses of GLP‑1 drugs for cosmetic slimming. She notes there is no scientific definition of “microd…
    STAT · 3mo agoNegative↗ source
  • GC Therapeutics appoints former BlueRock executive Stefan Irion as chief scientific officer
    GC Therapeutics announced that Stefan Irion has joined the company as its new chief scientific officer. Irion previously served in the same capacity at BlueRock Therapeutics. Irion brings experien…
    STAT · 3mo agoNeutral↗ source
← prev
page 74 of 89
next →
fda recalls67
fda medwatch60
fda press38
1127
Psychiatry & CNS864
Ophthalmology494
Pain478
Endocrinology & Metabolism468
Infectious Disease444
GSK and Ionis report functional cure in 20% of hepatitis B patients with bepirovirsen in early trials
GSK and Ionis disclosed results from two clinical studies of their RNA‑based injection, bepirovirsen, aimed at achieving a functional cure for chronic hepatitis B. In both trials about one‑fifth o…
BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • CVS adds Lilly’s Foundayo and Zepbound to formularies, leveling GLP-1 market with Novo
    CVS Caremark announced it will place Eli Lilly’s new oral GLP-1 drug Foundayo on its formulary starting June 1 and will restore the injectable Zepbound as a preferred option from Oct 1. The change…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • U.S. policy bars Ebola patients from entering country, plans overseas evacuation
    U.S. health officials announced that any American who contracts Ebola will not be taken to the United States for care. Instead, patients will be moved to undisclosed locations in Europe for treatme…
    STAT · 3mo agoRegulatoryNegative↗ source
  • 23andMe partners with HealthEx to let users import medical records for a 360-degree health view
    23andMe announced a partnership with HealthEx that will let its customers import their medical records, creating a more complete view of personal health. The new feature will combine genetic data…
    STAT · 3mo agoDealPositive↗ source
  • Supreme Court refuses to hear pharma challenges to Medicare price negotiation program
    The U.S. Supreme Court declined to review lawsuits filed by several brand‑name drug makers against the Medicare drug price negotiation program, dealing a significant setback to the industry. The c…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Mentari Therapeutics to go public via reverse merger with InMed, raising $290 million for migraine antibody programs
    Mentari Therapeutics, a spinout of Paragon, announced a reverse merger with InMed Pharmaceuticals that will take the company public under the Mentari name. The deal has received board approval fro…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Virginia Governor Vetoes Bill to Create Drug-Cost Advisory Panel Using Medicare Benchmarks
    Virginia's governor, Abigail Spanberger, vetoed a bill that would have created a new advisory panel aimed at lowering prescription-drug costs. The legislation had been closely watched as a potentia…
    STAT · 3mo agoRegulatoryNegative↗ source
  • AI tool guides Mayo clinicians to rapid treatment for newborn with ultra-rare disease
    An AI system called the Biomedical Data Translator was used by doctors at the Mayo Clinic to search for a therapy for a newborn with an ultra-rare disease. The infant, Jorie Kraus, was born with s…
    STAT · 3mo agoPositive↗ source
  • Former FDA commissioner sees hope for stability under new acting leader Kyle Diamantas
    At a recent STAT Breakthrough Summit West, former FDA commissioner David Kessler addressed concerns about the agency’s recent turmoil and staff departures. Kessler said the appointment of acting c…
    STAT · 3mo agoRegulatoryPositive↗ source
  • BioMarin's BMN-401 fails key endpoint in ENPP1 deficiency Phase 3 trial
    An experimental therapy, BMN 401, was tested in a Phase 3 study for ENPP1 deficiency, a rare disease. The drug missed one of its two co-primary endpoints, a result that regulators consider critical…
    BioPharma Dive · 3mo agoNegative readoutNegative↗ source
  • Relay Therapeutics reports promising Phase 2 results for zovegalisib; Eli Lilly leads R&D performance ranking
    Relay Therapeutics announced positive Phase 2 data for its experimental drug zovegalisib, which targets rare diseases that cause abnormal blood vessel development. The company said the results were…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Relay Therapeutics' zovegalisib shows 60% response in mid‑stage trial for rare vascular anomalies
    Relay Therapeutics reported early data from a phase 2 trial of its experimental drug zovegalisib in patients with vascular anomalies, a group of rare disorders characterized by abnormal blood vesse…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • Eli Lilly Leads Both Innovation and Invention Rankings in Pharma R&D Performance
    STAT+ reports that Eli Lilly captured the top positions in a prominent pharma R&D performance ranking, leading both the innovation and invention categories. The rankings, compiled by UK-based IDEA…
    STAT · 3mo agoPositive↗ source
  • Over 1 in 8 U.S. Pregnant Women Report Alcohol Use, Raising Fetal Health Concerns
    More than one in eight pregnant adults in the United States reported drinking in the past month, according to STAT's analysis of 2024 government data, making alcohol use more common than gestationa…
    STAT · 3mo agoNegative↗ source
  • UK adopts tobacco-free generation law, mirroring Massachusetts policy
    The United Kingdom has passed a tobacco‑free generation law that bars retailers from selling cigarettes, vapes or nicotine pouches to anyone born on or after Jan. 1, 2009. Existing customers may co…
    STAT · 3mo agoRegulatoryPositive↗ source
  • Heart transplant patient warns of 'ghost approval' gap that leaves life-saving drugs out of reach
    A heart transplant recipient and patient advocate describes how the medication everolimus (Zortress) is essential to prevent organ rejection, not an optional treatment. The author coins the term "…
    STAT · 3mo agoNegative↗ source
  • Trump-era foreign aid cuts likely hampered Ebola detection and response in Congo
    The United States reduced funding for programs that help prevent and control infectious diseases in the Democratic Republic of Congo during the final months before a fast-moving Ebola outbreak, acc…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Out-of-network spine surgery bills soar to $34,000 under No Surprises Act arbitration
    A new analysis shows that the median price for a lumbar laminectomy, a common spine surgery, is about $1,400 when performed by in-network providers. When the same procedure is done by out-of-netwo…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Study finds many Canadian medical societies lack robust conflict-of-interest policies
    A new analysis of 68 Canadian medical societies shows that just under half have comprehensive conflict-of-interest policies. The researchers identified that 35 societies, or about 52%, do not addre…
    STAT · 3mo agoNegative↗ source
  • TrumpRx expands generic drug lineup through partnership with Mark Cuban, Amazon Pharmacy and GoodRx
    TrumpRx said it is adding a range of generic medicines to its portfolio after striking a deal that includes Mark Cuban, Amazon Pharmacy and GoodRx. The agreement is expected to broaden the company…
    STAT · 3mo agoDealNeutral↗ source
  • Dexcom CEO discusses future applications of continuous glucose monitors and provides updates on WiSeR and Epic market share
    Dexcom's chief executive spoke about potential new uses for the company's continuous glucose monitoring technology, suggesting that the device could play a broader role in health management beyond…
    STAT · 3mo agoNeutral↗ source
  • Former Stanford President Marc Tessier-Lavigne Addresses Allegations in New Book
    Former Stanford President Marc Tessier-Lavigne, now chief executive of AI drug‑discovery startup Xaira, spoke publicly for the first time at the STAT Breakthrough Summit West in San Francisco. Dur…
    STAT · 3mo agoNeutral↗ source
  • U.S. imposes 30‑day travel ban on travelers from DRC, Uganda, South Sudan amid Ebola outbreak
    The CDC announced a new order that bars anyone who has been in the Democratic Republic of the Congo, Uganda, or South Sudan within the past 21 days from entering the United States. The restriction…
    STAT · 3mo agoRegulatoryNeutral↗ source